

Cyclophosphamide

Essential medicine status

General description

Cyclophosphamide is an antineoplastic alkylating agent, used in the treatment of many cancers.

INN

Cyclophosphamide

ATC codes

[L01AA01](#)

Medicine type

Chemical agent

EML status history

First added in 1977 ([TRS 615](#)) for [Diffuse large B-cell lymphoma, not otherwise specified](#)

Added in 1977 ([TRS 615](#)) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)

Added in 1977 ([TRS 615](#)) for [Rhabdomyosarcoma primary site](#)

Added in 1977 ([TRS 615](#)) for [Hodgkin lymphoma](#)

Added in 1977 ([TRS 615](#)) for [Other specified malignant neoplasms of breast](#)

Added in 1977 ([TRS 615](#)) for [Follicular lymphoma](#)

Added in 1977 ([TRS 615](#)) for [Malignant trophoblastic neoplasms of placenta](#)

Added in 1977 ([TRS 615](#)) for [Malignant neoplasms of breast](#)

Added in 1977 ([TRS 615](#)) for [Burkitt lymphoma including Burkitt leukaemia](#)

Added in 1977 ([TRS 615](#)) for [Lymphoid leukaemia, not elsewhere classified](#)

Added in 1977 ([TRS 615](#)) for [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)

Added in 1977 ([TRS 615](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2019 ([TRS 1021](#)) for [Plasma cell myeloma](#)

Added in 2021 ([TRS 1035](#)) for [Other specified gliomas of brain](#)

Added in 2021 ([TRS 1035](#)) for [Malignant neoplasms of kidney, except renal pelvis](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-positive](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-negative](#)

Wikipedia

[Cyclophosphamide](#)

DrugBank

[Cyclophosphamide](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg
- Oral > Solid: 25 mg tablet
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Indications

[Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Malignant neoplasms of breast](#) [Malignant trophoblastic neoplasms of placenta](#) [Follicular lymphoma](#) [Other specified malignant neoplasms of breast](#) [Hodgkin lymphoma](#) [Rhabdomyosarcoma primary site](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Plasma cell myeloma](#) [Other specified gliomas of brain](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Anaplastic large cell lymphoma, ALK-negative](#)